CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
The chart shows the growth of an initial investment of $10,000 in CVS HEALTH CORPORATION, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
CVS HEALTH CORPORATION (CVS) has returned -7.30% so far this year and 18.53% over the past 12 months. Looking at the last ten years, CVS has achieved an annualized return of -3.40%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of CVS HEALTH CORPORATION (CVS) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.00% | 7.45% | -10.10% | 1.98% | ||||||||
| 2025 | 25.21% | 17.19% | 3.03% | -1.67% | -11.67% | 8.61% | -9.70% | 17.38% | 3.30% | 3.78% | 2.95% | -0.76% |
| 2024 | -5.74% | -0.08% | 6.87% | -15.08% | 6.43% | -0.12% | 1.91% | -5.98% | 9.93% | -10.38% | 5.48% | -24.81% |
| 2023 | -3.82% | -5.08% | -10.36% | -2.29% | -7.56% | 1.16% | 8.06% | -12.83% | 6.76% | -0.76% | 3.35% | 16.27% |
| 2022 | 3.60% | -2.47% | -1.94% | -5.02% | 0.31% | -4.85% | 3.09% | 3.32% | -2.68% | -1.33% | 7.68% | -8.81% |
| 2021 | 4.32% | -5.48% | 9.95% | 1.56% | 12.26% | -3.54% | -1.61% | 4.89% | -1.44% | 5.28% | -0.79% | 14.39% |
| 2020 | -9.15% | -13.48% | -2.21% | 6.58% | 7.86% | -0.72% | -3.12% | -2.10% | -5.82% | -4.00% | 19.20% | -0.13% |
| 2019 | 1.06% | -10.34% | -7.26% | 0.41% | -7.88% | 3.71% | 1.40% | 9.18% | 4.35% | 5.05% | 12.58% | -1.24% |
| 2018 | 7.71% | -13.50% | -8.11% | 12.52% | -8.44% | 0.78% | 1.44% | 15.75% | 4.99% | -8.43% | 10.26% | -18.30% |
| 2017 | -0.97% | 2.45% | -3.21% | 5.18% | -6.80% | 4.71% | -1.04% | -3.20% | 4.87% | -15.76% | 11.30% | -4.13% |
| 2016 | -2.77% | -4.03% | -0.75% | -3.30% | 0.89% | -4.88% | -5.28% | -8.83% | 2.99% |
The charts below present risk-adjusted performance metrics for CVS HEALTH CORPORATION (CVS) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CVS compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current CVS HEALTH CORPORATION volatility is 1.35%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 249.73B | 228.28B | 233.00B | 230.72B | 222.45B | 196.46B | 95.13B | 94.46B | 93.66B | 74.25B | 71.53B | 65.91B | 64.54B | 61.64B |
| Temporary Equity (USD) | - | - | - | - | - | - | - | - | 39.00M | - | - | - | - | - |
| Equity Attributable To Parent (USD) | 76.46B | 71.02B | 75.08B | 69.39B | 63.86B | 58.23B | 37.69B | 36.83B | 37.20B | 37.96B | 37.94B | 37.70B | 38.05B | 35.77B |
| Equity Attributable To Noncontrolling Interest (USD) | 175.00M | 300.00M | 306.00M | 312.00M | 306.00M | 318.00M | 4.00M | 4.00M | 7.00M | 5.00M | - | - | - | - |
| Equity (USD) | 76.64B | 71.32B | 75.38B | 69.70B | 64.17B | 58.54B | 37.70B | 36.83B | 37.20B | 37.96B | 37.94B | 37.70B | 38.05B | 35.77B |
| Redeemable Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | 39.00M | - | - | - | - | - |
| Commitments and Contingencies (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Non-current Liabilities (USD) | - | - | - | - | - | 20.48B | 1.09B | 5.68B | 5.79B | 4.96B | 4.76B | 5.32B | 5.24B | - |
| Long-term Debt (USD) | - | - | - | - | - | 73.43B | 25.70B | 25.70B | 27.50B | 12.30B | 13.40B | 9.10B | 9.30B | - |
| Noncurrent Liabilities (USD) | 93.90B | 87.22B | 89.81B | 99.00B | 104.98B | 93.90B | 26.79B | 31.38B | 33.29B | 17.26B | 18.16B | 14.42B | 14.54B | 13.57B |
| Other Current Liabilities (USD) | - | - | - | - | - | - | 21.79B | 18.30B | 15.68B | 12.48B | 9.88B | 8.72B | 7.59B | 8.74B |
| Accounts Payable (USD) | - | - | - | - | - | - | 8.86B | 7.95B | 7.49B | 6.55B | 5.55B | 5.07B | 4.37B | 3.56B |
| Current Liabilities (USD) | 79.19B | 69.74B | 67.81B | 62.02B | 53.30B | 44.01B | 30.65B | 26.25B | 23.17B | 19.03B | 15.43B | 13.79B | 11.96B | 12.30B |
| Liabilities (USD) | 173.09B | 156.96B | 157.62B | 161.01B | 158.28B | 137.91B | 57.44B | 57.63B | 56.45B | 36.29B | 33.59B | 28.21B | 26.49B | 25.87B |
| Other Non-current Assets (USD) | 152.64B | 124.97B | 131.07B | 130.60B | 139.03B | 103.34B | 39.98B | 39.73B | 39.55B | 29.65B | 28.06B | 27.68B | 27.61B | 26.05B |
| Intangible Assets (USD) | 29.23B | 24.75B | 29.03B | 31.14B | 33.12B | 36.52B | 13.63B | 13.51B | 13.88B | 9.77B | 9.53B | 9.75B | 9.87B | 10.13B |
| Fixed Assets (USD) | - | 12.87B | 12.90B | 12.61B | - | 11.35B | 10.29B | 10.18B | 9.86B | 8.84B | 8.62B | 8.63B | 8.47B | 7.92B |
| Noncurrent Assets (USD) | 181.87B | 162.59B | 172.99B | 174.35B | 172.15B | 151.21B | 63.90B | 63.42B | 63.28B | 48.27B | 46.20B | 46.06B | 45.95B | 44.10B |
| Other Current Assets (USD) | 49.83B | 46.59B | 42.25B | 37.87B | 32.79B | 28.79B | 15.93B | 16.28B | 16.38B | 14.05B | 14.28B | 9.09B | 8.55B | 7.19B |
| Inventory (USD) | 18.03B | 19.09B | 17.76B | 18.50B | 17.52B | 16.45B | 15.30B | 14.76B | 14.00B | 11.93B | 11.05B | 10.76B | 10.05B | 10.34B |
| Current Assets (USD) | 67.86B | 65.68B | 60.01B | 56.37B | 50.30B | 45.24B | 31.23B | 31.04B | 30.38B | 25.98B | 25.33B | 19.85B | 18.59B | 17.54B |
| Assets (USD) | 249.73B | 228.28B | 233.00B | 230.72B | 222.45B | 196.46B | 95.13B | 94.46B | 93.66B | 74.25B | 71.53B | 65.91B | 64.54B | 61.64B |
A $100 investment in CVS Health five years ago would be worth $108.11 today, representing only 1.6% annual growth. This significantly underperforms the S&P 500, which would have grown to $171.46 (11% annually). CVS faces headwinds including pressure on profit margins from rising costs and limited rate increases for its Medicare Advantage plans, though it offers a solid 3.62% dividend yield.
NATPAT, a plant-based wellness brand, announced the launch of its BuzzPatch mosquito repellent and MagicPatch itch relief patches at over 4,700 CVS Pharmacy locations across 48 states starting March 20, 2026. The DEET-free patches offer chemical-free alternatives to conventional sprays and creams, marking the company's largest brick-and-mortar retail expansion to date.
Following recent market pullbacks, two healthcare stocks stand out as recovery opportunities: CVS Health, which faces Medicare Advantage reimbursement pressures but benefits from its diversified business model, and AbbVie, whose strong-performing immunology drugs Skyrizi and Rinvoq are offsetting Humira's patent-driven decline while maintaining a 54-year dividend increase streak.
Bioliberty, a healthtech startup, announced a $10.2 million Series A funding round led by the Scottish National Investment Bank ($4M) to expand its Lifehub Clinic platform with computer vision and care coordination capabilities. The company also launched Lifehub Home for at-home therapy tracking. Russell Bailey from Lifepoint Health and Dana Prommel Strauss from CVS Health joined the board, bringing healthcare expertise to support U.S. commercialization.
CVS Health announced that its board of directors approved a quarterly dividend of $0.665 per share on common stock, payable on May 4, 2026, to shareholders of record on April 23, 2026.
Parkman Healthcare Partners established a new $20 million position in EyePoint Pharmaceuticals by purchasing 1.088 million shares in Q4 2025. EyePoint shares have surged 93% over the past year as the company advances DURAVYU, a sustained-release therapy for retinal diseases, with Phase 3 trial data expected mid-2026. Despite significant losses and development-stage operations, the company has sufficient cash runway into late 2027.
Glenview Capital Management initiated a new $96.45 million position in DigitalOcean Holdings during Q4 2025, acquiring 2,004,299 shares. The investment became the fund's 11th-largest holding at 1.96% of AUM. DigitalOcean reported strong earnings with 18% revenue growth, 123% spike in ARR from $1M+ customers, and 150% AI ARR growth, positioning itself as a platform for high-growth cloud and AI workloads.
The article recommends two healthcare stocks for February 2026: CVS Health and Vertex Pharmaceuticals. CVS Health is positioned for long-term profitable growth after a strong 2025 rebound, with plans to streamline its Medicare Advantage and Obamacare businesses. Vertex Pharmaceuticals is expected to see strong commercial progress from newer drug launches (Casgevy and Journavx) and important clinical developments in 2026, diversifying beyond its core cystic fibrosis franchise.
Salvation Army has relocated from Gordon Plaza to a new 19,000 square foot space at Woodbridge Shopping Center in Virginia, positioned at the corner of Route 1 and Occoquan Road. The move follows Gordon Plaza's closure for redevelopment and allows Salvation Army to maintain its presence in the Woodbridge corridor with improved visibility and traffic. The shopping center is co-anchored by CVS and Dixie Bones.
The global clinical analytics market is experiencing rapid expansion driven by widespread EHR adoption, AI/ML advancements, and real-world evidence acceptance. The market is projected to grow at a 19.7% CAGR from $33.09 billion in 2025 to $81.32 billion by 2030, with Asia-Pacific leading regional growth. Key drivers include digital health adoption, value-based care transition, and precision medicine demand.
